While additional blood-based assays have been developed to augment imaging techniques, the serum protein biomarkers currently employed for NSCLC—including carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and SCC antigen—continue to display inadequate diagnostic specificity and sensitivity (Huang et al., 2022; Saman et al., 2022). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.